Family-directed umbilical cord blood banking

Umbilical cord blood transplantation from HLA-identical siblings provides good results in children. These results support targeted efforts to bank family cord blood units that can be used for a sibling diagnosed with a disease which can be cured by allogeneic hematopoietic stem cell transplantation or for research that investigates the use of allogeneic or autologous cord blood cells. Over 500 patients transplanted with related cord blood units have been reported to the Eurocord registry with a 4-year overall survival of 91% for patients with non-malignant diseases and 56% for patients with malignant diseases. Main hematologic indications in children are leukemia, hemoglobinopathies or inherited hematologic, immunological or metabolic disorders. However, family-directed cord blood banking is not widely promoted; many cord blood units used in sibling transplantation have been obtained from private banks that do not meet the necessary criteria required to store these units. Marketing by private banks who predominantly store autologous cord blood units has created public confusion. There are very few current validated indications for autologous storage but some new indications might appear in the future. Little effort is devoted to provide unbiased information and to educate the public as to the distinction between the different types of banking, economic models and standards involved in such programs. In order to provide a better service for families in need, directed-family cord blood banking activities should be encouraged and closely monitored with common standards, and better information on current and future indications should be made available.

[1]  F. Appelbaum,et al.  Hematopoietic cell transplantation with autologous cord blood in patients with severe aplastic anemia: An opportunity to revisit the controversy regarding cord blood banking for private use , 2011, Pediatric blood & cancer.

[2]  M. Geyer,et al.  Cord blood transplantation and stem cell regenerative potential. , 2011, Experimental hematology.

[3]  M. Mabed The potential utility of bone marrow or umbilical cord blood transplantation for the treatment of type I diabetes mellitus. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  A. Soldatou,et al.  Low usage rate of banked sibling cord blood units in hematopoietic stem cell transplantation for children with hematological malignancies: implications for directed cord blood banking policies. , 2011, Blood cells, molecules & diseases.

[5]  A. Tichelli,et al.  Controversies in hybrid banking: attitudes of Swiss public umbilical cord blood donors toward private and public banking , 2011, Archives of Gynecology and Obstetrics.

[6]  Jérôme Larghero,et al.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.

[7]  F. Locatelli,et al.  Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. , 2010, Blood.

[8]  Jessica M Sun,et al.  Differences in quality between privately and publicly banked umbilical cord blood units: a pilot study of autologous cord blood infusion in children with acquired neurologic disorders , 2010, Transfusion.

[9]  Frederic D. Bushman,et al.  Efficacy of gene therapy for X-linked severe combined immunodeficiency. , 2010, The New England journal of medicine.

[10]  C. Petrini Umbilical cord blood collection, storage and use: ethical issues. , 2010, Blood transfusion = Trasfusione del sangue.

[11]  D. Wall Regulatory issues in cord blood banking and transplantation. , 2010, Best practice & research. Clinical haematology.

[12]  V. Kitra,et al.  Directed sibling donor cord blood banking for children with beta-thalassemia major in Greece: usage rate and outcome of transplantation for HLA-matched units. , 2010, Blood cells, molecules & diseases.

[13]  J. Wagner,et al.  Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood , 2009, British journal of haematology.

[14]  E. Gluckman,et al.  Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft‐ and transplantation‐related factors , 2009, British journal of haematology.

[15]  Yvonne W. Cheng,et al.  Cost-effectiveness of Private Umbilical Cord Blood Banking , 2009, Obstetrics and gynecology.

[16]  Stephanie J. Lee,et al.  Private Cord Blood Banking: Experiences and Views of Pediatric Hematopoietic Cell Transplantation Physicians , 2009, Pediatrics.

[17]  R. Atun,et al.  Public-private partnership in cord blood banking , 2008, BMJ : British Medical Journal.

[18]  K. Ballen,et al.  Collection and preservation of cord blood for personal use. , 2008, Biology of Blood and Marrow Transplantation.

[19]  S. Watt,et al.  Directed Sibling Cord Blood Banking for Transplantation: The 10‐Year Experience in the National Blood Service in England , 2007, Stem cells.

[20]  B. Lubin,et al.  Cord Blood Banking for Potential Future Transplantation , 2007, Pediatrics.

[21]  B. Lubin,et al.  Sibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program , 2005, Annals of the New York Academy of Sciences.

[22]  V. Mironov,et al.  Can Routine Commercial Cord Blood Banking Be Scientifically and Ethically Justified? , 2005, PLoS medicine.

[23]  J. Wagner,et al.  Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. , 2004, The New England journal of medicine.

[24]  M. Labopin,et al.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. , 2004, The New England journal of medicine.

[25]  S. Rechitsky,et al.  Preimplantation HLA testing. , 2004, JAMA.

[26]  B. Lubin,et al.  Comprehensive banking of sibling donor cord blood for children with malignant and nonmalignant disease. , 2003, Blood.

[27]  J. Klein,et al.  Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. , 2000, The New England journal of medicine.

[28]  ohn,et al.  The GRAFT-VERSUS-HOST DISEASE IN CHILDREN WHO HAVE RECEIVED A CORD-BLOOD OR BONE MARROW TRANSPLANT FROM AN HLA-IDENTICAL SIBLING , 2000 .

[29]  J. Adamson,et al.  The Placental/Umbilical Cord Blood Program of the New York Blood Center A Progress Report , 1999, Annals of the New York Academy of Sciences.

[30]  P. Wernet,et al.  NETCORD: a cord blood allocation network. , 1998, Bone marrow transplantation.

[31]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors , 1997 .

[32]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. , 1997, The New England journal of medicine.

[33]  J. Kurtzberg,et al.  Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. , 1996, The New England journal of medicine.

[34]  J. Wagner,et al.  Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease , 1995, The Lancet.

[35]  J. Kurtzberg,et al.  Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. , 1989, The New England journal of medicine.